Drugs / P-188 NF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03558958 | Aug 2018 → Sep 2021 | Duchenne muscular dystrophy | Phrixus Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-188 NF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03558958 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT03558958 ↗ |